Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alvimopan.

Paul Neary1, Conor P Delaney

  • 1Department of Colorectal Surgery/A-30, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA.

Expert Opinion on Investigational Drugs
|May 11, 2005
PubMed
Summary
This summary is machine-generated.

Alvimopan, a mu-receptor opioid antagonist, effectively speeds gastrointestinal recovery after surgery and alleviates opioid-induced bowel issues. Clinical trials show it is safe and comparable to placebo for adverse events.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A multi-omic biomarker signature in pre-treatment rectal tumours stratifies patients with different pathological responses to neoadjuvant treatment.

Clinical and translational medicine·2025
Same author

A Connected Care platform for ostomates: a feasibility study.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract·2025
Same author

Evaluating the use of absorbable sutures versus sTaples versus tIssue glue in laparoscopic port skin closure (STILS) trial: A prospective, multi-centre randomised clinical trial (RCT).

The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland·2025
Same author

Longer Term Outcomes of Laparoscopic Peritoneal Lavage in the Management of Acute Hinchey III Perforated Diverticulitis: A Systematic Review and Meta-Analysis.

Digestive surgery·2024
Same author

Early Heart Failure Outcomes and Medical Therapy Use in a Virtually Managed Hospital at Home Setting.

JACC. Heart failure·2024
Same author

Complement is increased in treatment resistant rectal cancer and modulates radioresistance.

Cancer letters·2024
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
Same journal

Darigabat and subtype-selective GABA-A modulation: pharmacology, clinical development, and translational challenges.

Expert opinion on investigational drugs·2026
Same journal

Safety, tolerability, and pharmacokinetics of HL-300, a novel topical pan-JAK inhibitor, in healthy Chinese adults: a first-in-human, randomized, double-blind, placebo-controlled phase I trial.

Expert opinion on investigational drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Drug Development

Background:

  • Alvimopan is a peripherally restricted mu-receptor opioid antagonist with high affinity for mu-opioid receptors.
  • Its molecular properties limit gastrointestinal absorption and central nervous system penetration, resulting in limited systemic bioavailability.
  • Alvimopan demonstrates higher affinity for the mu-opioid receptor compared to naloxone.

Purpose of the Study:

  • To assess the efficacy of Alvimopan in accelerating gastrointestinal recovery post-abdominal surgery.
  • To evaluate Alvimopan's effectiveness in managing opioid-induced bowel dysfunction in patients with chronic opioid use.
  • To review the safety profile and potential clinical applications of Alvimopan.

Main Methods:

  • Review of completed Phase III clinical trials.

Related Experiment Videos

  • Assessment of pharmacological properties, including receptor binding affinity and bioavailability.
  • Analysis of adverse event data compared to placebo groups.

    • Main Results:

    • Phase III trials indicate Alvimopan accelerates gastrointestinal function recovery after abdominal surgery.
    • Efficacy has also been demonstrated in alleviating opioid-induced bowel dysfunction.
    • Adverse events were found to be similar across all doses and placebo groups.

    Conclusions:

    • Alvimopan shows significant efficacy in improving postoperative gastrointestinal recovery.
    • The drug is a promising option for managing opioid-induced bowel dysfunction.
    • Further evaluation supports Alvimopan's potential role in clinical practice for gastrointestinal care.